Update shared on 14 Nov 2025
Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.
Analyst Commentary
Recent analyst updates highlight both optimism and caution regarding Azenta's growth prospects and valuation trajectory.
Bullish Takeaways- Bullish analysts anticipate meaningful growth drivers ahead. They cite the firm's healthy exposure to the biopharma sector as a positive factor.
- Innovation, improved pricing power, and increased attach rates are expected to enhance the company’s mid-term opportunity and support a higher share price.
- Potential acquisitions are viewed as additional levers for expanding Azenta’s market position and accelerating revenue growth.
- There is growing confidence that the company can be valued higher as investors recognize Azenta’s execution on these catalysts.
- Bears remain cautious about the ability to consistently achieve anticipated growth from innovation and pricing strategies.
- Some raise concerns regarding the execution risk connected to integrating new acquisitions and maintaining robust attach rates.
- Certain analysts are mindful of the current valuation. They note that increasing confidence in the mid-term outlook will be required to support further upside.
What's in the News
- Announced a strategic partnership with the PRECEDE Foundation to provide secure storage of study samples and optimize logistics for pancreatic cancer research. This initiative supports improved early detection and survival rates. (Key Developments)
- Azenta recently held its Analyst/Investor Day, where the company highlighted its business strategy and growth outlook. (Key Developments)
Valuation Changes
- Fair Value remains stable at $35.17 per share, showing no significant change from previous assessments.
- The Discount Rate has increased slightly, rising from 7.34% to 7.81%.
- Revenue Growth projections are unchanged and hold steady at approximately 0.78% year over year.
- Net Profit Margin estimates remain consistent at just over 5%.
- The Future P/E has risen marginally from 58.02x to 58.78x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.